All Skewed Up
Executive SummaryThe enormous valuation that Neoforma..com achieved in its January IPO, which followed the enormous valuation Ventro Corp. has achieved as a public company has the entire hospital supply industry buzzing. But much of the discussion has to do, plain and simple, with the phenomenal amounts of money executives at these companies have made--at least on paper--as a result of their companies' astronomical valuations.
You may also be interested in...
CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.